JPH0491036A - External preparation for anus - Google Patents
External preparation for anusInfo
- Publication number
- JPH0491036A JPH0491036A JP20788090A JP20788090A JPH0491036A JP H0491036 A JPH0491036 A JP H0491036A JP 20788090 A JP20788090 A JP 20788090A JP 20788090 A JP20788090 A JP 20788090A JP H0491036 A JPH0491036 A JP H0491036A
- Authority
- JP
- Japan
- Prior art keywords
- external preparation
- anus
- agent
- hemorrhoids
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000436 anus Anatomy 0.000 title abstract description 5
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 10
- 239000003429 antifungal agent Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 17
- 208000014617 hemorrhoid Diseases 0.000 abstract description 19
- 239000004615 ingredient Substances 0.000 abstract description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 239000003883 ointment base Substances 0.000 abstract description 3
- -1 thioconazole Chemical compound 0.000 abstract description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract description 2
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004022 clotrimazole Drugs 0.000 abstract description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 abstract description 2
- 229960003645 econazole nitrate Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 229960004884 fluconazole Drugs 0.000 abstract description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 229960004125 ketoconazole Drugs 0.000 abstract description 2
- 229930188428 trichomycin Natural products 0.000 abstract description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
- 229960003942 amphotericin b Drugs 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 230000002439 hemostatic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960005040 miconazole nitrate Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- 206010048946 Anal abscess Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、痔疾患の治療に用いられる肛門用外用薬剤に
関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to an external anal drug used for the treatment of hemorrhoidal diseases.
［従来の技術］
痔疾患治療用の薬剤として、東洋医学に基礎をおく生薬
を中心とする薬剤と、西洋医学に基礎をおく化学薬剤の
２つの系統のものがあった。[Prior Art] There are two types of drugs for the treatment of hemorrhoids: drugs based on herbal medicines based on Oriental medicine, and chemical drugs based on Western medicine.
そして東洋医学系の薬剤、いわゆる漢方医薬は生薬を多
種類配合したものであるが、その処方は経験的に使用を
積み重ねて改良が進められてきたものである。Oriental medicine-based medicines, so-called Chinese herbal medicines, are a combination of many types of crude drugs, and their prescriptions have been improved through experience and repeated use.
また西洋医学系の医薬は、それぞれ特有の生理活性を有
する薬効成分を、いくつか絹み合わせてなるものであり
、痔疾治療剤としては、例えば塩酸ジブカイン、リドカ
インなどの局所麻酔性の鎮痛剤、例えばヒドロコルチゾ
ンなどの副腎皮質ホルモン、例えばエスクロシト、テト
ラヒドロ−１，４−オキサジン塩酸塩、乳酸アルミニウ
ム、次没食子酸ビスマスなどの止血剤、例えば硫酸フラ
ジオマイシン「ヘキサクロロフェンなどの消毒剤」、例
えば塩酸ジフェンヒドラミンなどの抗ヒスタミン剤など
の各種の成分から適宜のものを選択して配合し、座薬ま
たは軟膏などに調製したものか普通であった。更に、シ
コンエキス等の生薬を追加して、西洋医学に東洋医学を
加味したものも作られている。In addition, Western medicine medicines are made by combining several medicinal ingredients, each with its own unique physiological activity. As hemorrhoid treatment agents, for example, local anesthetic analgesics such as dibucaine hydrochloride and lidocaine, Corticosteroids such as hydrocortisone, hemostatic agents such as escrocyto, tetrahydro-1,4-oxazine hydrochloride, aluminum lactate, bismuth subgallate, fradiomycin sulfate, disinfectants such as hexachlorophene, diphenhydramine hydrochloride, etc. It was common to select and mix appropriate ingredients from various ingredients such as antihistamines and prepare them into suppositories or ointments. Furthermore, products that incorporate Western medicine and Oriental medicine are also made by adding crude drugs such as Sikon extract.
「発明が解決しようとする課題」
痔疾患は、痔疾、痔核、４肛の３態様に分類されるが、
このようなそれぞれの態様を発現するに至る医学上の統
一的な定説はない。``Problem to be solved by the invention'' Hemorrhoid diseases are classified into three types: hemorrhoids, hemorrhoids, and 4-anus.
There is no unified medical theory that leads to the manifestation of each of these aspects.
しかし痔疾に関しては、肛門小窩炎が肛門膣炎にまで進
行し、更に奥に進んで肛門周囲膿瘍となり、肛門周囲の
皮膚を破って排膿して痔瑠となる、とされており、また
痔核は、排便時のいきみや飲酒等により肛門うっ血が起
こり、静脈瘤が形成されて痔核となる、とされている。However, when it comes to hemorrhoids, it is said that anal fossa inflammation progresses to anal vaginitis, which progresses further to become a perianal abscess, which ruptures the skin around the anus and drains, forming hemorrhoids. Hemorrhoids are said to be caused by anal congestion caused by straining during defecation, drinking alcohol, etc., and varicose veins are formed, resulting in hemorrhoids.
更に４肛は、便秘により固くて太い便が排泄されるとき
に、肛門管の皮膚を引き裂くことにより発生する、とさ
れている。そして、これらの痔疾は、肛門小窩炎、肛閂
洞炎、肛門膣炎などの炎症により増悪するであろうと推
測されているものの、医学上の証明はなされていない。Furthermore, it is said that anus 4 occurs when the skin of the anal canal is torn when hard and thick stools are excreted due to constipation. Although it is assumed that these hemorrhoids are exacerbated by inflammation such as anal fossitis, anal sinusitis, anorovaginitis, etc., no medical proof has been provided.
ところでこうした痔疾に、従来の痔疾治療剤による止血
と鎮痛を主とした治療を加えたときはしばしば再発をく
りかえし、更に抗生物質などの抗菌剤を加えた治療剤を
用いても完治は望み難かったわ
このような事情において、本発明は従来の肛門用薬剤よ
りも優れた痔疾患治療効果を発揮する新規な肛門用外用
薬剤を提供することを目的とした。However, when such hemorrhoids are treated with conventional hemorrhoid treatment drugs that mainly stop bleeding and provide pain relief, recurrences often occur, and even with treatments that include antibiotics and other antibacterial agents, it is difficult to hope for a complete cure. Under these circumstances, the present invention aimed to provide a novel topical anal drug that exhibits a more effective therapeutic effect on hemorrhoids than conventional anal drugs.
［課題を解決するための手段］
本発明の目的は、有効量の抗真菌剤を含有することを特
徴とする肛門用外用薬剤によって達成することができる
。[Means for Solving the Problems] The objects of the present invention can be achieved by an external anal preparation characterized by containing an effective amount of an antifungal agent.
本発明の外用薬剤に配合含有させる抗真菌剤としては、
アンホテリミンＢ１硝酸ミコナゾール、硝酸エコナゾー
ル、チオコナゾール、クロトリマゾール、トリコマイシ
シ、フルコナゾール、ケトコナゾールなどが好ましく用
いられるが、必ずしもこれらに限られるものではない。The antifungal agent to be incorporated into the external drug of the present invention includes:
Amphoterimine B1 miconazole nitrate, econazole nitrate, tioconazole, clotrimazole, trichomycin, fluconazole, ketoconazole and the like are preferably used, but are not necessarily limited to these.
また、これらの抗真菌剤は軟膏基剤中に有効量、たとえ
ば０．０１重量％以上の濃度となるよ°うに配合して用
いることができる。Further, these antifungal agents can be incorporated into the ointment base in an effective amount, for example, at a concentration of 0.01% by weight or more.
さらに本発明の外用薬剤には、消炎剤、抗菌剤、鎮痛剤
、止血剤、消毒剤などの各種の薬効成分を配合すること
ができ、それによって−層優れた治療効果を発揮させる
ことができる。Furthermore, the external medicine of the present invention can contain various medicinal ingredients such as anti-inflammatory agents, antibacterial agents, analgesics, hemostatic agents, and disinfectants, thereby making it possible to exhibit excellent therapeutic effects. .
［実施例］
抗菌剤として抗生物質ゲンタマイシンＩＯｍｐ、抗真菌
剤として硝酸ミコナゾール１００ＴＩＩＣ＋、消炎剤と
してヒドロコルチゾン２．５ｍｇ、生体活性剤として太
陽菌死菌浮遊液０．ｌ６３ｙｆ、消毒剤として水溶性ア
ズレン ３ ｇ ％および水０．５ｇを軟膏基剤２１ｇ
とよく混合して、本発明の軟膏形の外用薬剤を調製した
。[Example] Antibiotic gentamicin IOmp as an antibacterial agent, miconazole nitrate 100TIIC+ as an antifungal agent, 2.5 mg of hydrocortisone as an anti-inflammatory agent, and 0.5 mg of killed sun bacteria suspension as a bioactive agent. l63yf, 3 g % water-soluble azulene as disinfectant and 0.5 g water as ointment base 21 g
The ointment-type external medicine of the present invention was prepared by mixing well with the following.
更に、比較のために抗真菌剤を配合しない従来の痔疾意
外用薬剤を使用した。Furthermore, for comparison, a conventional drug for treating hemorrhoids without an antifungal agent was used.
本発明の軟膏を痔疾患者の患部に対して約０．２〜０．
３ｇ塗布したところ、肛門部の痛みの消失や出血の停止
までの時間が比較品使用の場合に比して著しく短縮され
た。Apply the ointment of the present invention to the affected area of a person suffering from hemorrhoids by approximately 0.2 to 0.
When 3g was applied, the time required for pain in the anus to disappear and bleeding to stop was significantly shorter than when using the comparison product.
そしてまた、本発明の外用薬剤を使用して治癒した患者
では痔疾の再発までの期間が延長していることが認めら
れた。Furthermore, it was observed that the period until recurrence of hemorrhoids was prolonged in patients who were cured using the topical drug of the present invention.
［発明の効果］
本発明の外用薬剤は抗真菌剤が含有されたものてあり、
抗真菌剤を含有しない従来の外用薬剤に較べて、痔疾の
治癒を早め、再発し難くすることにより、患者の負担を
著しく軽減できる利点がある。[Effect of the invention] The external medicine of the present invention contains an antifungal agent,
Compared to conventional external medicines that do not contain antifungal agents, this drug has the advantage of speeding up the healing of hemorrhoids and making recurrence difficult, thereby significantly reducing the burden on patients.
特許出願人 橋 岡 龍 世間 日本クリンゲージ株式会社Patent applicant: Hashi Oka Ryu Sekai Japan Clingage Co., Ltd.
Claims (1)
用薬剤。An external anal drug characterized by containing an effective amount of an antifungal agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2207880A JPH0692317B2 (en) | 1990-08-06 | 1990-08-06 | Topical anal drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2207880A JPH0692317B2 (en) | 1990-08-06 | 1990-08-06 | Topical anal drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0491036A true JPH0491036A (en) | 1992-03-24 |
| JPH0692317B2 JPH0692317B2 (en) | 1994-11-16 |
Family
ID=16547090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2207880A Expired - Lifetime JPH0692317B2 (en) | 1990-08-06 | 1990-08-06 | Topical anal drug |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0692317B2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993007884A1 (en) * | 1991-10-25 | 1993-04-29 | Senju Pharmaceutical Co., Ltd. | External preparation for treating hemorrhoidal diseases |
| EP0608308A1 (en) * | 1991-10-15 | 1994-08-03 | MASON, Kenneth Vincent | Anti-seborrhoeic formulation |
| GR980100028A (en) * | 1998-01-15 | 1999-09-30 | Drug Research Hellas ����� | Pharmaceutical products for local use containing fluconazole in concentrations between 0.2 % and 5 % |
| WO2000023058A3 (en) * | 1998-10-16 | 2000-07-06 | Vitabiotics Limited | Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids |
| US7189761B2 (en) | 1994-05-27 | 2007-03-13 | Gorfine Stephen R | Nitric oxide donor composition and method for treatment of anal disorders |
| KR100794853B1 (en) * | 2002-10-10 | 2008-01-15 | 게이 캐롤 엘. | Composition for treating hemorrhoids |
| JP2012025771A (en) * | 2011-10-14 | 2012-02-09 | Taisho Pharmaceutical Co Ltd | Cooling agent-containing gelled agent for treating hemorrhoid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63174923A (en) * | 1987-01-08 | 1988-07-19 | イー・アール・スクイブ・アンド・サンズ・インコーポレイテッド | Vital body adhesive suppository medicine |
-
1990
- 1990-08-06 JP JP2207880A patent/JPH0692317B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63174923A (en) * | 1987-01-08 | 1988-07-19 | イー・アール・スクイブ・アンド・サンズ・インコーポレイテッド | Vital body adhesive suppository medicine |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0608308A1 (en) * | 1991-10-15 | 1994-08-03 | MASON, Kenneth Vincent | Anti-seborrhoeic formulation |
| EP0608308A4 (en) * | 1991-10-15 | 1995-06-07 | Kenneth Vincent Mason | Anti-seborrhoeic formulation. |
| WO1993007884A1 (en) * | 1991-10-25 | 1993-04-29 | Senju Pharmaceutical Co., Ltd. | External preparation for treating hemorrhoidal diseases |
| US7189761B2 (en) | 1994-05-27 | 2007-03-13 | Gorfine Stephen R | Nitric oxide donor composition and method for treatment of anal disorders |
| GR980100028A (en) * | 1998-01-15 | 1999-09-30 | Drug Research Hellas ����� | Pharmaceutical products for local use containing fluconazole in concentrations between 0.2 % and 5 % |
| WO2000023058A3 (en) * | 1998-10-16 | 2000-07-06 | Vitabiotics Limited | Use of an antianaerobic-bacterial or/and antiprotozoal agent (preferably metronidazole) in the manufacture of a medicament for the treatment of haemorrhoids |
| KR100794853B1 (en) * | 2002-10-10 | 2008-01-15 | 게이 캐롤 엘. | Composition for treating hemorrhoids |
| US8790686B2 (en) | 2002-10-10 | 2014-07-29 | L. Gaye Carroll | Method and composition for treating hemorrhoids |
| JP2012025771A (en) * | 2011-10-14 | 2012-02-09 | Taisho Pharmaceutical Co Ltd | Cooling agent-containing gelled agent for treating hemorrhoid |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0692317B2 (en) | 1994-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207024A (en) | Fast-acting drug to treat sexual dysfunction | |
| US4118480A (en) | Pharmaceutical preparation for treating hemorrhoids and anal fissures | |
| AU2310200A (en) | Pharmaceutical compositions | |
| CN108853312A (en) | Lauromacrogol external-use gel and preparation method thereof | |
| CN106109451A (en) | A kind of antibiotic preparation and preparation method thereof | |
| JPH0491036A (en) | External preparation for anus | |
| WO2001043735A1 (en) | Nitroglycerin ointment for treatment of pain associated with anal disease | |
| CN109316550A (en) | A kind of cleaning is antibacterial to use care agent | |
| US20070078417A1 (en) | Method and system for systematically treating hemorrhoids | |
| EP1663195B1 (en) | Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition | |
| RU2177314C2 (en) | Composition eliciting antiseptic, reparative and analgetic properties | |
| Groel | Dimethyl Sulfoxide as a Vehicle for Corticosteroids: A Comparison With the Occlusive Dressing Technique | |
| EP1218063B1 (en) | Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic acid and menthol for topical application and process for the preparation thereof | |
| JP2000119186A (en) | Sucralfate-containing pharmaceutical composition for local administration | |
| CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
| RU2144834C1 (en) | Paper sanitary-hygienic material | |
| US20050013821A1 (en) | Mint extract and related pharmaceutical compositions | |
| Yuryeva et al. | Choice of the base of extemporaneous suppositories with xeroform | |
| RU2262925C2 (en) | Gel-like preparation for local anesthesia | |
| CN1050988C (en) | Medicinal paper for treating haemorrhoids and protecting anus | |
| RU2310455C2 (en) | Composition for hemorrhoid treatment | |
| Boddu et al. | Excipients and non-medicinal agents as active pharmaceutical ingredients | |
| WO2014204416A1 (en) | A solution used in the treatment of hemorrhoid | |
| KR20100032514A (en) | Composition and the manufacturing method of the pharmacy treatment and inflammation prevention of the postoperative anal wound | |
| CN105031507A (en) | Flos carthami tincture antibacterial liquid and preparation method thereof |